Monthly Prescribing Reference

Phase 2 study of NPI-2358 for non-small cell lung cancer

Nereus Pharmaceuticals announced that it is conducting a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) NPI-2358. The ADVANCE (Assessment of Docetaxel and Vascular ...
Yahoo Finance

Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression

FORT WORTH, Texas, April 30, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ...
Medscape

Do Registered Nurses Need a National Provider Identifier (NPI)?

I believe that registered nurses need to apply for NPI numbers in certain situations. Where and how can I learn more? Adjunct Clinical Faculty, Graduate Nursing, Washington State University, Vancouver ...
Monthly Prescribing Reference

Phase 2 trial of plinabulin (NPI-2358) for the treatment of advanced non-small cell lung cancer (NSCLC)

Nereus Pharmaceuticals announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard ...